Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ED recall

This article was originally published in The Tan Sheet

Executive Summary

Jack Distribution voluntarily recalls selected lots of its dietary supplements Rize 2 The Occasion Capsules and Rose 4 Her Capsules because they contain the undeclared ingredient thiomethisosildenafil, an analog of an FDA-approved erectile dysfunction drug, the Pompano Beach, Fla.-based firm announces July 1. The nationwide recall is the latest in a string of recalls in the last few months as FDA cracks down on ED supplements with unapproved drugs (1"The Tan Sheet" June 2, 2008, In Brief)...

You may also be interested in...



ED supplement crackdown

FDA has requested that SEI Pharmaceuticals recall Xiadafil VIP Tabs and warns that the product, which is marketed as a dietary supplement for erectile dysfunction, is actually an unapproved drug, the agency says in a May 27 release. The product contains hydroxyhomosildenafil, which is an analog of sildenafil, the active ingredient in Viagra. The same ingredient was found in International Pharmaceuticals' supplement Viril-Lty-Power, which the company voluntarily recalled after being informed by FDA of the product's adulteration, a May 29 release states. The recalls occur as supplements marketed for treatment of ED are frequently being found to contain undeclared ingredients (1"The Tan Sheet" Jan. 28, 2008, p. 11). Health Canada also warned consumers May 22 not to use the ED product Desire from StarChem Labs because it includes the undeclared drug phentolamine...

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Topics

UsernamePublicRestriction

Register

PS101843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel